Objectives: To investigate the predictive value of the quantitative T2-FLAIR mismatch ratio (qT2FM) with fully automated tumor segmentation in adult-type diffuse lower-grade gliomas (LGGs).

Materials And Methods: This retrospective study included 218 consecutive patients (mean age, 47 years ± 15 [SD]; 125 males) diagnosed with adult-type diffuse LGG. The cohort was classified into IDH wild-type (IDHwt), IDH-mutant with 1p/19q-codeletion (IDHmut-Codel), and IDH-mutant without 1p/19q-codeletion (IDHmut-Noncodel) subtypes. Tumor masks were obtained using deep learning-based segmentation, and qT2FM was calculated from the differences in signal intensity ratios on T2 and FLAIR images. Multivariable logistic regression identified predictors for identifying IDHmut-Noncodel and IDH mutation status. Point-biserial correlations were analyzed between qualitative and quantitative T2FM, and median apparent diffusion coefficient (ADC) value. Diagnostic performance was evaluated with a receiver operating characteristic curve.

Results: The IDHmut-Noncodel group had a higher qT2FM (0.37 ± 0.38, p = 0.004) than the IDHmut-Codel (0.24 ± 0.39) and IDHwt groups (0.07 ± 0.62). The qT2FM was the only independent imaging predictor for identifying IDHmut-Noncodel (OR = 3.43, 95% CI: 1.30-9.05, p = 0.01). Independent predictors of IDH mutation were younger age (p < 0.001), frontal lobe location (p = 0.007), cortical involvement (p < 0.001), and higher qT2FM (p = 0.034). The qT2FM significantly correlated with visual T2FM (vT2FM) and median ADC value. Adding qT2FM to vT2FM improved performance in identifying IDHmut-Noncodel (AUC 0.77, 95% CI: 0.70-0.82) and IDH mutation status (AUC 0.77, 95% CI: 0.71-0.83) than each parameter alone.

Conclusion: The qT2FM ratio, derived from deep learning-based tumor segmentation, is a valuable predictor for identifying IDH mutation status and the IDHmut-Noncodel subtype in patients with adult-type diffuse LGG.

Key Points: Question Does deep-learning-based quantification of the T2-FLAIR mismatch sign provide accurate prediction of IDH-mutant, 1p/19q non-codeleted astrocytomas and enhance identification of IDH mutation status? Findings Quantifying the T2-FLAIR mismatch sign with a fully automated segmentation tool achieved high accuracy in identifying IDH-mutant, 1p/19q non-codeleted astrocytomas, and enhanced IDH status prediction. Clinical relevance Integrating the qT2FM into clinical protocols enhances diagnostic precision and guides treatment strategies, underscoring the role of advanced imaging in neuro-oncology.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00330-025-11475-7DOI Listing

Publication Analysis

Top Keywords

idh mutation
12
adult-type diffuse
12
deep learning-based
8
t2-flair mismatch
8
diffuse lower-grade
8
idh-mutant 1p/19q-codeletion
8
identifying idhmut-noncodel
8
learning-based quantification
4
quantification t2-flair
4
mismatch sign
4

Similar Publications

Purpose To develop and evaluate an automated system for extracting structured clinical information from unstructured radiology and pathology reports using open-weights language models (LMs) and retrieval augmented generation (RAG) and to assess the effects of model configuration variables on extraction performance. Materials and Methods This retrospective study utilized two datasets: 7,294 radiology reports annotated for Brain Tumor Reporting and Data System (BT-RADS) scores and 2,154 pathology reports annotated for mutation status (January 2017 to July 2021). An automated pipeline was developed to benchmark the performance of various LMs and RAG configurations for structured data extraction accuracy from reports.

View Article and Find Full Text PDF

Purpose: Alternating electric fields (AEF) therapy in addition to temozolomide chemoradiotherapy (TMZ CRT) is increasingly being recommended as first-line treatment for patients with newly-diagnosed WHO grade 4 astrocytoma. However, few have validated this treatment with real-world evidence.

Methods: Consecutive adult patients with newly-diagnosed WHO grade 4 astrocytoma treated with adjuvant TMZ CRT across all neuro-oncology centers in Hong Kong were reviewed.

View Article and Find Full Text PDF

Non-canonical roles for growth factors in the nucleus have been previously described, but their mechanism of action and biological roles remain enigmatic. Platelet-derived growth factor B (PDGFB) can drive formation of low-grade glioma and here we show that it localizes to the nucleus of human glioma cells where it binds chromatin to preserve genome stability and cell lineage. Failure of PDGFB to localize to the nucleus leads to chromosomal abnormalities, aberrant heterochromatin architecture and accelerated tumorigenesis.

View Article and Find Full Text PDF

Mutations in isocitrate dehydrogenase 1 and 2 genes (IDH1 and IDH2) are found in 15% to 20% of patients with acute myeloid leukemia (AML). IDH inhibitors have been introduced as targeted treatment and are currently under investigation as maintenance therapy after allogeneic transplantation (allo-SCT). Since reports about the outcome of IDH1- and IDH2-mutated (IDHmut) AML after allo-SCT are limited, we retrospectively analyzed 356 IDH-mutated AML patients (IDH1 40%, IDH2 60%).

View Article and Find Full Text PDF

Background: The current understanding of glioma pathogenesis is limited by the lack of comprehensive insights into the metabolic reprogramming associated with isocitrate dehydrogenase (IDH) mutations. This study aims to contribute a step to this gap by investigating the role of energy metabolism-related genes in glioma. Our objective is to identify key molecular markers that could serve as prognostic markers and potential therapeutic targets for more effective treatment strategies in IDH-mutant glioma patients.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!